La cadena de opciones muestra datos clave de las opciones de acciones de Coherus Oncology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Coherus Oncology..

Coherus Oncology (NASDAQ:CHRS) Bolsa, Cadena de Opciones

COHERUS ONCOLOGY INC

Coherus BioSciences

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Coherus Oncology Inc

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 13.8% to $4.46 during Thursday's after-market session. The company's market cap stands at $13.1 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 11.11% to $0.45. The company's market cap stands at $20.7 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares rose 10.29% to $6.43. The company's market cap stands at $100.6 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock rose 9.85% to $0.7. The company's market cap stands at $74.9 million. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) stock rose 9.17% to $14.76. The market value of their outstanding shares is at $613.0 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares moved upwards by 9.02% to $1.45. The company's market cap stands at $78.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock declined by 16.6% to $2.36 during Thursday's after-market session. The company's market cap stands at $5.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 14.97% to $19.55. The company's market cap stands at $5.1 billion. As per the news, the H1 earnings report came out 3 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock decreased by 9.09% to $10.11. The company's market cap stands at $6.1 million. </li>
<li>Coherus Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares declined by 8.62% to $0.74. The company's market cap stands at $92.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 6.38% to $0.87. The market value of their outstanding shares is at $2.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 5.87% to $0.71. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BBNX

CGTX

CHRS

INDP

LIXT

NTHI

PROK

SONN

TRIB

WINT

12 Health Care Stocks Moving In Thursday's After-Market Session

Coherus BioSciences, Inc.&nbsp;(("Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and endometrial cancer.

News

Coherus BioSciences Announces Clinical Collaboration With STORM Therapeutics To Evaluate STC-15, METTL3 Inhibitor, In Combination With LOQTORZI, Next-Gen PD-1 Inhibitor, In Phase 1b/2 Study For NSCLC, HNSCC, Melanoma And Endometrial Cancer Treatment

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 90.1% to $2.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 25.15% to $0.19. The market value of their outstanding shares is at $4.7 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 23.11% to $0.9. The market value of their outstanding shares is at $46.5 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares moved upwards by 21.22% to $14.05. The company's market cap stands at $381.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) shares moved upwards by 11.22% to $4.26. The market value of their outstanding shares is at $201.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock rose 10.49% to $2.21. The market value of their outstanding shares is at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 91.8% to $0.03 during Tuesday's pre-market session. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock decreased by 36.8% to $0.47. The market value of their outstanding shares is at $106.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 21.63% to $0.11. The company's market cap stands at $2.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares declined by 19.73% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock fell 16.67% to $0.85. The market value of their outstanding shares is at $98.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 16.59% to $0.35. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCT

AXDX

CNSP

ENTO

GCTK

KLTO

PLRZ

RDHL

SGMO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

WIIM

Coherus BioSciences shares are trading lower. The company reported Q1 financial results.

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.35) per share. This is a 27.08 percent increase over losses of $(0.48) per share from the same period last year. The company reported $7.60 million in sales this quarter. This is a 229.25 percent increase over sales of $2.31 million the same period last year.

Earnings

Coherus BioSciences Q1 Adj. EPS $(0.35) Up From $(0.48) YoY, Sales $7.60M Up From $2.31M YoY

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Coherus BioSciences will report an earnings per share (EPS) of $-0.15.
Investors in Coherus BioSciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.15 in the last quarter, leading to a 0.96% increase in the share price on the following day.
Here's a look at Coherus BioSciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.16</td>
<td>-0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.01</td>
<td>-0.14</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>13.0%</td>
<td>11.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746821155_0.png" alt="eps graph" />
<h3>Performance of Coherus BioSciences Shares</h3>
Shares of Coherus BioSciences were trading at $0.9923 as of May 08. Over the last 52-week period, shares are down 53.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CHRS/earnings">To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Coherus BioSciences

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

&ndash; CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab &ndash;
&ndash; Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab &ndash;
&ndash; A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026&ndash;
&ndash; Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time&ndash;
REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.&nbsp;((&quot;Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>), today announced data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) evaluating two pharmacologically active doses of CHS-114 for dose optimization. These data are being presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

Coherus Biosciences Presents Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab

Coherus BioSciences shares are trading higher after the company announced it completed UDENYCA franchise divestiture.

&nbsp;– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –
– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI&#xAE;, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 (IL-27) antagonist; – CHS-114, a highly selective CCR8 (chemokine receptor 8) antibody –
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) today announced the completion of the previously announced divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise (the Transaction) to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million. Coherus received an upfront payment of $483.4 million, including $118.4 million for UDENYCA inventory, and is eligible to receive potential milestone payments of up to $75 million.
"With strong strategic execution, we have transformed the company while dramatically reducing our debt and leaving $250 million on the post-close balance sheet. This provides ample runway to achieve our mid-term corporate objectives, including maximizing LOQTORZI revenues, advancing our novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progressing label expanding indications for LOQTORZI in novel combinations," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "Coherus is now an innovative, revenue-generating oncology company with a strong balance sheet, and a promising mid-stage pipeline focused on unmet needs."
Terms of the Transaction and Financial Details At the closing of the Transaction, which occurred on April 11, 2025, Coherus received an upfront cash payment of $483.4 million, subject to certain adjustments that will be finalized following the closing pursuant to the Agreement. After the closing, Coherus is eligible to receive two milestone payments totaling $75.0 million if Intas meets specified thresholds of net sales of UDENYCA. At the closing, Intas received identified assets related to the UDENYCA franchise, including the UDENYCA pre-filled syringe, the UDENYCA autoinjector, and UDENYCA ONBODY&#xAE;, and assumed identified liabilities. At the closing, <a href="https://www.globenewswire.com/Tracker?data=BxhYF1sknRX4WjYKx0BBTTPwbmAmDdVgEPfBhKVSTTFNqsWmvrO9Hr3HNoK_v_-soJNfxKQ6jip2NaxsAqB96R6vTb2CxProPKPAt6z0YjEAztVJRFu3m46VuYhp_tZUPF9DXPFeXrh4QxbPqbabLclhbbihUh65jnHAvLSWYL7gRYkvf7Fhz0Jz9j3lz0k-MWCZR4OzX2BtD-zA9zyxuy-y6ss_i-_0ezaaijPn9xE=">Accord BioPharma</a>, Inc. (Accord), the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, assumed full responsibility for the UDENYCA franchise in the U.S.

Biotech

Guidance

Asset Sales

General

Coherus Completes Strategic Transformation With Successful Divestiture Of UDENYCA Franchise; Says $250M Post-Close Cash Balance Extends Cash Runway Over 2-Years Into 2027, Funding Pipeline Development Through Key Data Catalysts; Coherus To Focus Exclusively On Its Innovative Novel Oncology Programs

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) announced today that it has entered into privately negotiated transactions (the "Repurchases") with certain holders (the "Holders") of its 1.500% Convertible Senior Subordinated Notes due 2026 (the "Convertible Notes"), pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount, together with the accrued and unpaid interest to, but excluding, the date of repurchase.
The Repurchases are conditioned upon, among other things, the closing of the previously announced divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise pursuant to that certain asset purchase agreement (the "Agreement"), dated as of December 2, 2024 between the Company and Intas Pharmaceuticals Ltd. ("Intas"), a limited company incorporated in India (the "Transaction").
Following the closing of the Repurchases, approximately $60 million aggregate principal amount of Convertible Notes will remain outstanding. Following the closing of the Transaction, Coherus intends to conduct a repurchase offer for such remaining Convertible Notes pursuant to the Fundamental Change Repurchase Right (as defined in the indenture, dated as of April 17, 2020 (the "Indenture"), between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee")) at a cash repurchase price equal to 100% of their principal amount, together with the accrued and unpaid interest to, but excluding, the date of repurchase.

Buybacks

Coherus Announces Repurchase Of ~$170M Of Convertible Notes

Coherus To Present Data From Phase 1 Dose Expansion Study Of CHS-114 At 2025 American Association For Cancer Research Annual Meeting

Coherus Biosciences Projects Post-UDENYCA-Close Cash Of ~$250M And Cash Runway Projections Exceeding Two Years, Past Key Data Readouts Expected In 2026.

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.13) by 115.38 percent. This is a 54.84 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $54.144 million which beat the analyst consensus estimate of $47.270 million by 14.54 percent. This is a 40.84 percent decrease over sales of $91.524 million the same period last year.

Earnings Beats

Earnings Misses

Coherus BioSciences Q4 2024 Adj. EPS $(0.28) Misses $(0.13) Estimate, Sales $54.144M Beat $47.270M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $305.85 million. 
• BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $1.15 billion. 
• UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) is estimated to report quarterly loss at $0.72 per share on revenue of $25.25 million. 
• DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is expected to report quarterly loss at $0.14 per share on revenue of $7.39 million. 
• Fennec Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $16.42 million. 
• Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) is estimated to report earnings for its first quarter. 
• Cohen &amp; Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COHN#AMEX">COHN</a>) is expected to report earnings for its fourth quarter. 
• Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $3.67 per share on revenue of $433 thousand. 
• Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) is estimated to report earnings for its fourth quarter. 
• Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $25.55 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is likely to report earnings for its fourth quarter. 
• Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) is estimated to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METCB#NASDAQ">METCB</a>) is projected to report earnings for its fourth quarter. 
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $176.04 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $215.50 million. 
• One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $239.77 million. 
• NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) is likely to report earnings for its fourth quarter. 
• Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.62 million. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is projected to report earnings for its fourth quarter. 
• Douglas Elliman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $233.65 million. 
• Great Elm Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GECC#NASDAQ">GECC</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $11.46 million. 
• Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $9.90 million. 
• Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is projected to report earnings for its fourth quarter. 
• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $14.39 billion. 
• Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is likely to report quarterly loss at $0.18 per share on revenue of $43.88 million. 
• Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) is likely to report quarterly loss at $0.18 per share on revenue of $75.58 million. 
• TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $84.38 million. 
• Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $384.99 million. 
• Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is likely to report quarterly loss at $0.07 per share on revenue of $158.36 million. 
• Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $59.40 million. 
• LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $57.34 million. 
• Seaport Entertainment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SEG#AMEX">SEG</a>) is likely to report earnings for its fourth quarter. 
• Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $149.37 million. 
• PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $67.73 million. 
• Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $23.78 million. 
• System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) is expected to report quarterly loss at $0.23 per share on revenue of $91.28 million. 
• Mission Produce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $272.00 million. 
• StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $222.06 million. 
• HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $246.32 million. 
• PGIM ETF Trust PGIM Portfolio Ballast ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/PBL#BATS">PBL</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $147.18 million. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $121.19 million. 
• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is projected to report quarterly earnings at $6.36 per share on revenue of $1.14 billion. 
• Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) is likely to report earnings for its fourth quarter. 
• Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $296.50 million. 
• Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is expected to report quarterly loss at $0.01 per share on revenue of $187.84 million. 
• Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.08 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGS

ASAN

AUNA

BNTX

COHN

CVGI

DOUG

DRIO

FENC

GECC

GLRE

HSAI

LCTX

LFMD

MYPS

NCSM

ORCL

RAND

SARO

STKS

SUPV

TBRG

URGN

WLFC

YALA

Earnings Scheduled For March 10, 2025

<a href="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view" title="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view">https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view</a>

Contracts

Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing

Coherus Biosciences Announced Final Data From Its Phase 2 Open Label Clinical Trial Evaluating Casdozokitug In Combination With Atezolizumab And Bevacizumab (Bev) In Treatment Naïve Patients With Unresectable Locally Advanced Or Metastatic Hepatocellular Carcinoma

Press Releases

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Health Care

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Coherus to Participate in Upcoming Investor Conferences

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Comments

Coherus Oncology

Coherus Oncology (CHRS) Opciones

Coherus Oncology (NASDAQ:CHRS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL